Evidence map›Paper›PMID 39704932›Full record

ArticleScience China. Life sciences2025

Gut microbiota's role in high-altitude cognitive impairment: the therapeutic potential of Clostridium sp. supplementation.

Wei Zhou, Yongqiang Zhou, Shikun Zhang, Bin Li, Zhong Li, Zhijie Bai, Dezhi Sun, Chaoji Huangfu, Ningning Wang, Tiantian Xia and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Science China. Life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Frontiers in microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Wei Zhou *Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing, 100850, China.
Yongqiang Zhou *Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing, 100850, China.
Shikun Zhang *Department of Stem Cell and Regenerative Medicine, Institute of Health Service and Transfusion Medicine, Beijing, 100850, China.
Bin Li *Mountain Sickness Research Institute, No.950 Hospital, Yecheng, 844900, China.
Zhong LiDepartment of Stomatology, the First Medical Center, Chinese PLA General Hospital, Beijing, 100853, China.
Zhijie BaiDepartment of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing, 100850, China.
Dezhi SunDepartment of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing, 100850, China.
Chaoji HuangfuDepartment of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing, 100850, China.
Ningning WangDepartment of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing, 100850, China.
Tiantian XiaMedical School of Qinghai University, Xining, 810016, China.
Congshu HuangDepartment of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing, 100850, China.
Lina GuanGeneral Hospital of Xinjiang Military Command, Urumqi, 830000, China.
Xi YangGeneral Hospital of Xinjiang Military Command, Urumqi, 830000, China.
Yangyi HuDepartment of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing, 100850, China.
Pengfei ZhangDepartment of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing, 100850, China.
Pan ShenDepartment of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing, 100850, China. spluto@foxmail.com.
Rui WangGeneral Hospital of Xinjiang Military Command, Urumqi, 830000, China. wangrui231218@126.com.
Zhexin NiDepartment of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing, 100850, China. nizxzg@163.com.
Yue GaoDepartment of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing, 100850, China. gaoyue@bmi.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prolonged exposure to high-altitude environments may increase the risk of cognitive decline in young migrants. Recent studies suggest that hypobaric hypoxia-induced alterations in gut microbial composition could partly contribute to this risk. However, the absence of direct evidence from cohort studies and an unclear mechanism hinder intervention development based on this hypothesis. This study recruited 109 young male migrants living in Xizang to investigate the microbial mechanisms underlying cognitive impairment associated with high-altitude migration. Multi-omic analysis revealed distinct microbiome and metabolome features in migrants with cognitive decline, notably a reduced abundance of Clostridium species and disrupted fecal absorption of L-valine. Mechanistic studies showed that hypobaric hypoxia significantly damaged the intestinal barrier, leading to lipopolysaccharide (LPS) leakage and an influx of inflammatory factors into the peripheral blood, which activated microglia and caused neuronal injury in the hippocampus of mice. Additionally, compromised L-valine absorption due to intestinal barrier damage correlated with lower hippocampal glutamate levels and neurotrophic factors. Intervention with Clostridium sp. effectively restored the intestinal barrier and enhanced L-valine absorption, which mitigated hypobaric hypoxia-induced inflammation and hippocampal neural damage in mice. In conclusion, cognitive impairment among young migrants at high altitude may be attributed to hypobaric hypoxia-induced gut microbiota disruption and subsequent intestinal barrier dysfunction. This study may provide a promising approach for preventing and treating high-altitude-associated cognitive impairment.

Indexed as

AltitudeAltitude SicknessClostridiumCognitive DysfunctionGastrointestinal MicrobiomeAdultAnimalsDietary SupplementsHippocampusHumansHypoxiaMaleMiceClostridium sp.cognition impairmenthigh-altitudeL-valinemicrobial mechanisms

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.